Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT06449482 2025-05-30

Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy

Phase 1/2 Terminated

6 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04421378 2024-12-16

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Phase 1/2 Terminated

74 enrolled 23 charts

CNS

Glioblastoma

NCT04768881 2024-08-23

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

Phase 2 Terminated

15 enrolled 15 charts

Dermatologic

Melanoma

NCT03095612 2024-06-13

Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Terminated

41 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04854434 2023-11-03

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

Phase 2 Terminated

13 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms

NCT04843579 2023-10-25

ClaSPd

Phase 2 Terminated

4 enrolled 9 charts

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03193437 2023-02-16

SELECT

Phase 2 Terminated

8 enrolled 11 charts

Thoracic

Thymoma

NCT01986348 2023-01-26

KING

Phase 2 Terminated

76 enrolled 16 charts

CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

NCT02138786 2023-01-26

SIRRT

Phase 2 Terminated

27 enrolled 17 charts

Richter's Transformation

NCT02146833 2023-01-26

SHIP

Phase 2 Terminated

20 enrolled 13 charts

Genitourinary

Prostatic Neoplasms

NCT02213133 2023-01-26

STARRS

Phase 2 Terminated

45 enrolled 12 charts

Tumor-Agnostic

Carcinoma, Carcinoma, Squamous Cell

NCT02314247 2023-01-26

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

Phase 2 Terminated

16 enrolled 16 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT05093608 2022-10-17

SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma

Phase 1 Terminated

2 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02384850 2022-04-08

SENTINEL

Phase 1 Terminated

10 enrolled 13 charts

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT03071276 2020-05-22

Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 2 Terminated

37 enrolled 11 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02215161 2018-06-26

Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

Phase 2 Terminated

14 enrolled 12 charts

Genitourinary

Castration Levels of Testosterone

NCT02351505 2016-05-16

Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer

Phase 2 Terminated

1 enrolled 6 charts

Thoracic

Small Cell Lung Carcinoma

NCT02283359 2016-01-15

Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

Phase 1 Terminated

3 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Neoplasm Metastasis, Recurrence, Stomach Neoplasms